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Quantification of exposure biomarkers is increasingly used to pro-
vide an integrated measure of a person’s multiple chemical-specific 
exposures (Pirkle et al. 1995). Yet successful exposure characterization 
requires more than sophisticated analytical chemistry techniques—the 
biomarker and matrix are also key. 
For general-population exposures, persistent organic pollutants 
(POPs) are usually measured in blood, and metabolites of non-
persistent chemicals such as phthalates and bisphenol A (BPA) are 
best measured in urine (Koch and Calafat 2009). In recent years, 
however, investigators have increasingly characterized exposure to 
nonpersistent chemicals by using other tissue matrices, particularly 
blood. To illustrate this trend, we identified 80 scientific articles, 
published in 2000–2014, that reported measuring BPA or phthal-
ates in blood serum/plasma and other nonaqueous matrices, and that 
addressed topics on etiology, exposure, or metabolism (Figure 1). 
Urine is the preferred matrix for most nonpersistent chemicals 
because of their pharmacokinetics. Nonpersistent chemicals are 
quickly transformed to hydrophilic, polar metabolites and excreted 
mainly in urine (Koch and Calafat 2009). The concentration of most 
urinary metabolites is 30–100 times greater than concentrations in 
blood (Engel and Wolff 2013; National Research Council 2008). 
With existing analytical techniques, higher urinary concentrations 
facilitate quantification, whereas relatively low blood concentrations of 
polar biomarkers increase the likelihood that external contamination 
obscures true exposures. 
These are paramount considerations, given the increasingly recog-
nized ubiquity of contamination. Controlled conditions of collection, 
storage, and processing of biospecimens are a long-acknowledged 
critical step for trace analyses of metals, volatile organic compounds, 
and POPs (Alcock et al. 1994; Ashley et al. 1992; Bolann et al. 2007). 
Unfortunately, the importance of preanalytic contamination sources 
is not as well understood for semivolatiles such as phthalates, phenols 
(e.g., BPA, parabens, triclosan), and similar modern  nonpersistent 
chemicals.
Rather than reflecting a person’s usual exposure over months 
to years, detected biomarkers of chemicals such as phthalates and 
BPA can represent recent use of medical equipment or treatment 
near the time of biospecimen collection (Jaeger and Rubin 1970; 
Larson et al. 1977; Vandentorren et al. 2011; Yan et al. 2009). 
Extraneous contamination may occur during both the preanalytical 
and analytical phases. Phthalates and BPA can be detected even in the 
cleanest laboratories, from reagents, sampling equipment, and analytical 
apparatus (Fankhauser-Noti and Grob 2007; Longnecker et al. 2013; 
Marega et al. 2013; Markham et al. 2010; Vandenberg et al. 2014). 
Extraneous phenols may also come from sources such as plastics or 
paper products (BPA), soap (triclosan), moist towelettes (parabens), and 
preservatives (BPA, parabens) (Guidry et al. 2015; Longnecker et al. 
2013; Ye et al. 2013). Moreover, in the field, during processing, or 
in the laboratory, beginning immediately after sample collection, 
phthalate diesters are hydrolyzed to monoesters by enzymes present in 
most biologic matrices (e.g., milk, serum, meconium, amniotic fluid, 
skin, saliva, sweat). These hydrolytic enzymes are not present in urine 
(Hines et al. 2009). In other words, monoesters are formed both from 
diesters absorbed in the body from a person’s general environment—the 
exposure we intend to assess—and from diesters introduced into the 
biospecimen itself from contaminated surfaces and medical devices.
Phase I (e.g., phthalate oxidative metabolites) and phase II (e.g., 
phenol conjugates) metabolite biomarkers are least likely to arise from 
extraneous sources (Koch and Calafat 2009). Also, these metabolites 
exist at higher levels than the hydrolytic monoesters or free (uncon-
jugated) phenols in urine (Hines et al. 2009; Teeguarden et al. 2013). 
For many phenols, no specific oxidative metabolites that can exclude 
contamination are currently used for biomonitoring. Instead, con-
jugated phenols (rather than the unconjugated species) are the most 
valid exposure biomarkers (Koch et al. 2012; Teeguarden et al. 2013).
The short half-life of nonpersistent chemicals presents additional 
challenges, in that a biomarker must meet the criterion of tempo-
rality. Regardless of the matrix, intraindividual variability exists in 
exposure metrics over short time periods, particularly when such 
exposures are episodic in nature (Frederiksen et al. 2013; Koch et al. 
2014; Lassen et al. 2013; Preau et al. 2010; Ye et al. 2011). However, 
metabolites are detectable longer in urine than in other matrices. 
Acceptable biomarker variability can exist because exposures arise from 
common, quotidian sources. Consequently, reasonable reproducibility 
over months to years has been found for urinary biomarker concen-
trations (Baird et al. 2010; Engel et al. 2014; Hauser et al. 2004; 
Mahalingaiah et al. 2008; Marcus et al. 2010; Meeker et al. 2012; 
Nepomnaschy et al. 2009; Teitelbaum et al. 2008; Townsend et al. 
2013). To improve exposure assessment, studies can also incorporate 
pooling of specimens or repeated measurements across the time win-
dow of interest, such as trimesters of pregnancy (Adibi et al. 2008; 
Braun et al. 2011; Cantonwine et al. 2014; Fisher et al. 2014; Irvin 
et al. 2010; Jusko et al. 2014; Meeker et al. 2013; Philippat et al. 2013; 
Quirós-Alcalá et al. 2013; Smith et al. 2012; Valvi et al. 2015). 
In population research, environmental agents are selected 
for study based on biological relevance and exposure prevalence. 
Exposure biomarkers should be based on pharmacokinetics of 
the target chemicals and a suitable sampling matrix. The design 
should incorporate appropriate control procedures for collecting 
and processing specimens, validated analytical methods, and statisti-
cal analyses that account for sampling issues such as urine dilution 
(Barr et al. 2005) and collection times (Calafat and Needham 2009). 
Technology has made it analytically possible to measure polar bio-
markers at trace concentrations in many media, but these endeavors 
risk exposure misclassification due to low biomarker concentrations, 
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Summary: We discuss considerations that are essential when evaluating 
exposure to nonpersistent, semivolatile environmental chemicals 
such as phthalates and phenols (e.g., bisphenol A). A biomarker 
should be chosen to best represent usual personal exposures and not 
recent, adventitious, or extraneous exposures. Biomarkers should be 
selected to minimize contamination arising from collection, sampling, 
or analysis procedures. Pharmacokinetics should be considered; for 
example, nonpersistent, semivolatile chemicals are metabolized quickly, 
and urine is the compartment with the highest concentrations of 
metabolites. Because these chemicals are nonpersistent, knowledge 
of intraindividual reliability over the biologic window of interest is 
also required. In recent years researchers have increasingly used blood 
as a matrix for characterizing exposure to nonpersistent chemicals. 
However, the biologic and technical factors noted above strongly 
support urine as the optimal matrix for measuring nonpersistent, 
 semivolatile, hydrophilic environmental agents.
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short biologic half-lives, and threat of external contamination. Greater 
reliance on phthalate and phenol biomarker concentrations in urine 
will improve the return on investment in environmental research. 
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